Cellecta, Inc.
Mountain View, CA Doing business as Cellecta Inc.
- UEI
- ENT1Z37DAHJ8
- CAGE
- 4GCV9
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 320 Logue Ave, Mountain View, CA 94043, USA
- Website
- cellecta.com
- Founded
- 2006
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Ncats: service: custom knock-in cell lines: non-severable | Office of Logisitics and Acquisition Operations | $19,185 | |
| Custom pooled crispr KO library | National Center for Advancing Translational Sciences | $14,000 | |
| Cellecta, incorporated:1145260 [24-004505] | National Institute on Drug Abuse | $24,000 | |
| Comprehensive crispr-CAS9 knockout (KO) screening to determine growth suppressor mutations in mouse embryonic stem… | Uniformed Services University of the Health Sciences | $0 | |
| Human genome-wide crispri dual-sgrna library (virus) | National Institute on Drug Abuse | $20,130 |
About Cellecta, Inc.
Cellecta, Inc., a for-profit manufacturer of genetic screening tools and services based in Mountain View, California, operates exclusively as a prime contractor supplying CRISPR-Cas9 knockout libraries, RNAi reagents, custom gene-edited cell lines, and functional genomics screening services to the National Institutes of Health. The vendor competes on full-and-open federal procurements with no set-aside designations across its recent award portfolio.
Cellecta's customer base is heavily concentrated within HHS. The top five funding entities by award count account for 80% of recent awards, dominated by the NIH's National Center for Advancing Translational Sciences (10 awards, $298 thousand combined potential value), the National Cancer Institute (6 awards, $1.6 million), and the National Institute on Drug Abuse (4 awards, $175 thousand). The National Center for Advancing Translational Sciences leads in award volume; the National Cancer Institute anchors most of the potential dollar value. Work is issued as firm fixed-price purchase orders with no parent vehicles or IDVs — each award stands alone. Recent representative work includes a $19,185 purchase order from NCATS for custom knock-in cell line development (May 2026), a $24,000 delivery from NCATS for genetic reagents and screening services (June 2024), a $70,400 purchase order from the National Institute on Drug Abuse for custom stable Cas9/dCas9-KRAB clonal cell lines (February 2023), and a $96,000 order from NCATS for flexible functional genomics platforms and complementary CRISPR screening infrastructure (September 2022).
Activity has declined sharply. The vendor moved four awards in 2022 and six in 2023, dropping to one award per year in 2024, 2025, and 2026. The combined potential value of recent awards stands at $2.1 million, but the obligated-dollars total across all awards is $11.7 million (551% of potential value), indicating historical volume and contract completions substantially exceed recent pipeline momentum. Two awards with ultimate completion dates in the next twenty-four months carry combined potential value of $33 thousand and face recompete. The vendor carries no subcontract footprint — all 41 awards in the source are prime contracts. Cellecta's capability portfolio centers on CRISPR-Cas9 and RNAi libraries (human and murine genome-wide), custom pooled and clonal cell line engineering, sgRNA library design and synthesis, and laboratory testing services, all directed at NIH intramural and extramural researchers in translational medicine, cancer biology, and drug abuse neuroscience.
SBA capabilities narrative
Screening and development of novel technologies, tools and drug targets to fight against cancer, biowarfare, infectious diseases, neurological disorders, blood diseases, aging, development disorders, and other human diseases.
Quick answers
What is Cellecta, Inc.'s UEI?
Cellecta, Inc.'s Unique Entity ID (UEI) in SAM.gov is ENT1Z37DAHJ8.
What is Cellecta, Inc.'s CAGE code?
Cellecta, Inc.'s CAGE code is 4GCV9.
What is Cellecta, Inc.'s primary NAICS code?
Cellecta, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Cellecta, Inc. located?
Cellecta, Inc.'s physical address in SAM.gov is 320 Logue Ave, Mountain View, CA 94043, USA.
Is Cellecta, Inc. registered in SAM.gov?
Yes. Cellecta, Inc.'s SAM.gov registration is active through January 26, 2027.
What is Cellecta, Inc.'s most recent federal award?
Cellecta, Inc.'s most recent federal contract award is Ncats: service: custom knock-in cell lines: non-severable (75N98026P00481), from Office of Logisitics and Acquisition Operations, on May 11, 2026.
On GovTribe
See Cellecta, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors